Alcon “Custom” LASIK Approval For Myopia Prohibits Superiority Claims
This article was originally published in The Gray Sheet
Executive Summary
Alcon hopes that surgeons will accept its LADARVision CustomCornea wavefront-guided laser vision correction system as superior to currently available LASIK systems, despite FDA approval conditions prohibiting claims of superiority
You may also be interested in...
B&L Looks To TV, Equipment Financing To Spur Zyoptix Wavefront LASIK Use
Bausch & Lomb will launch a TV ad campaign for the Zyoptix custom wavefront ablation system upon FDA approval by year-end, Senior VP and CFO Stephen McCluski said at the Bear Stearns annual healthcare conference in New York Sept. 9
B&L Looks To TV, Equipment Financing To Spur Zyoptix Wavefront LASIK Use
Bausch & Lomb will launch a TV ad campaign for the Zyoptix custom wavefront ablation system upon FDA approval by year-end, Senior VP and CFO Stephen McCluski said at the Bear Stearns annual healthcare conference in New York Sept. 9
Ophthalmic Spin-Offs Alcon, AMO See Stock Gains In 2002, Join MDDI Index
Ophthalmic device makers Alcon and Advanced Medical Optics (AMO) were both able to achieve double-digit stock price percentage gains in 2002 after debuting as independent firms, in part due to expanding sales of surgical products such as IOLs